Table 1 Characteristics of pSS patients and the control subjects
pSS (n = 116) | Control (n = 46) | |
|---|---|---|
Age (years) | 47.8 ± 13.8 | 46.5 ± 12.1 |
Sex (female/male) | 110/6 | 42/4 |
Disease duration (months) | 49.6 ± 5.4 | – |
Interstitial lung disease (ILD), n (%) | 17 (14.6) | – |
Fever, n (%) | 1 (0.9) | – |
Hypocytosis, n (%) | 29 (25.0) | – |
Arthritis, n (%) | 5 (4.3) | – |
Glandular swelling, n (%) | 3 (2.5) | – |
Purpura, n (%) | 5 (4.3) | – |
Anemia, n (%) | 7 (6.0) | – |
Leukopenia, n (%) | 15 (12.9) | – |
Thrombocytopenia, n (%) | 10 (8.6) | – |
Lymphopenia, n (%) | 7 (6.0) | – |
Renal disease, n (%) | 9 (7.7) | – |
Autoimmune liver dysfunction, n (%) | 3 (2.5) | – |
Pulmonary arterial hypertension (PAH), n (%) | 3 (2.5) | – |
ANA positive | 112 (96.6) | – |
A-SSA positive | 98 (84.5) | – |
A-SSB positive | 44 (37.9) | – |
IgG (g/L) | 18.8 ± 6.0 | – |
IgA (g/L) | 3.3 ± 1.4 | – |
IgM (g/L) | 1.6 ± 0.9 | – |
C3 (g/L) | 1.0 ± 0.2 | – |
C4 (g/L) | 0.2 ± 0.1 | – |
ESR (mm/H) | 30.1 ± 26.2 | – |
RF positive | 46 (39.7) | – |
CD4+ T cell% | 36.2 ± 9.6 | |
CD8+ T cell% | 27.4 ± 10.1 | |
NK cell% | 12.4 ± 7.0 | |
CD19 cell% | 14.4 ± 8.3 | |
ESSDIA | 0 to 24 (4.7 ± 4.8) | – |
ESSPRI | 0 to 7.3 (3.7 ± 1.7) | |
Focus Index (1–3) | 0 to 7 (2.0 ± 1.5) | – |